Peptide Science research editorial team.
BPC-157 plus TB-500 10mg Blend Overview
BPC-157 plus TB-500 10mg Blend from Peptide Science is a dual-active lyophilised vial pairing the synthetic 15-amino-acid pentadecapeptide BPC-157 with the 7-amino-acid active fragment of Thymosin Beta-4 (TB-500, positions 17 to 23). The blend supplies both compounds in one reconstitution event, supporting comparison studies where researchers want to observe combined-pathway effects in a single experimental arm.
Combined Mechanism Profile
The two compounds act on distinct but adjacent pathways. BPC-157 has been characterised in preclinical studies for VEGFR2-receptor activation and FAK-paxillin signalling, both relevant to angiogenesis and fibroblast migration. TB-500 sequesters G-actin and modulates cell-migration signalling via a separate route. When the two are co-administered in cell-culture or animal-model protocols, published comparisons have looked for additive or synergistic effects on tissue-repair markers. See the parent healing peptides collection for the broader catalogue.
Vial Specifications
| Property | Value |
|---|---|
| Active 1 | BPC-157, 15-amino-acid pentadecapeptide |
| Active 2 | TB-500, 7-amino-acid active fragment of Thymosin Beta-4 (positions 17 to 23) |
| Combined strength | 10 mg total per vial |
| Supplied form | Lyophilised powder, sealed vial |
| Purity | each active greater than 99 percent (HPLC and mass-spec verified) |
| Storage | 2 to 8 degrees Celsius lyophilised; minus 20 degrees Celsius long-term |
For the higher-strength 20 mg total format of the same blend, see BPC-157 plus TB-500 20mg Blend.
Reconstitution and Handling
The lyophilised dual-active vial is typically reconstituted with bacteriostatic water for stability and assay-concentration studies. Researchers planning separate-active dosing should source the single-compound vials individually: BPC-157 5mg for the pentadecapeptide alone, and the standalone TB-500 listings for the beta-thymosin fragment.
Verification and Shipping
Each batch passes HPLC at greater than 99 percent for each active, with mass-spectrometry confirmation of both compounds. A signed Certificate of Analysis ships with every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in temperature-monitored packaging via overnight or two-day courier. For four-compound combination work that adds the cathelicidin tripeptide KPV and the copper tripeptide GHK-Cu, see BPC-157 plus TB-500 plus KPV plus GHK-Cu 80mg Klow Blend.
For laboratory research and development use only. Not for human or veterinary consumption. Has not been evaluated by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws. Lyophilised vials store at 2 to 8 degrees Celsius; protect from light.
Reviews
There are no reviews yet.